- Home
- GNFT vs ADCT Comparison
GNFT vs ADCT Comparison
Compare GNFT & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- ADCT
- Stock Information
- Founded
- GNFT 1999
- ADCT 2011
- Country
- GNFT France
- ADCT Switzerland
- Employees
- GNFT N/A
- ADCT N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- GNFT Health Care
- ADCT Health Care
- Exchange
- GNFT Nasdaq
- ADCT Nasdaq
- Market Cap
- GNFT 296.4M
- ADCT 224.3M
- IPO Year
- GNFT 2019
- ADCT 2020
- Fundamental
- Price
- GNFT $3.90
- ADCT $2.97
- Analyst Decision
- GNFT Strong Buy
- ADCT Strong Buy
- Analyst Count
- GNFT 1
- ADCT 5
- Target Price
- GNFT $13.00
- ADCT $7.33
- AVG Volume (30 Days)
- GNFT 7.9K
- ADCT 897.3K
- Earning Date
- GNFT 09-19-2024
- ADCT 11-07-2024
- Dividend Yield
- GNFT N/A
- ADCT N/A
- EPS Growth
- GNFT N/A
- ADCT N/A
- EPS
- GNFT 0.47
- ADCT N/A
- Revenue
- GNFT $86,225,222.00
- ADCT $70,717,000.00
- Revenue This Year
- GNFT $155.44
- ADCT $6.38
- Revenue Next Year
- GNFT N/A
- ADCT $11.73
- P/E Ratio
- GNFT $8.13
- ADCT N/A
- Revenue Growth
- GNFT 175.45
- ADCT N/A
- 52 Week Low
- GNFT $3.31
- ADCT $0.94
- 52 Week High
- GNFT $6.42
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- GNFT 24.88
- ADCT 41.63
- Support Level
- GNFT $4.00
- ADCT $1.80
- Resistance Level
- GNFT $4.24
- ADCT $2.38
- Average True Range (ATR)
- GNFT 0.11
- ADCT 0.20
- MACD
- GNFT -0.02
- ADCT 0.00
- Stochastic Oscillator
- GNFT 2.65
- ADCT 52.27
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.